新加坡成年人在奥密克戎传播期间接种COVID-19疫苗或SARS-CoV-2检测阳性后的死亡与心血管事件风险
这项回顾性队列研究纳入2022年1月6日至12月31日奥密克戎流行期间≥18岁新加坡成年人,评估mRNA疫苗接种后或SARS-CoV-2感染后0-180天全因死亡和心血管事件风险。结果显示疫苗接种后各年龄层均未见死亡或心血管事件风险升高,而感染后老年人在急性期后心血管风险升高,但感染前180天内接种疫苗可减弱此风险。
要点
- 接种mRNA疫苗后180天内各年龄层均未观察到全因死亡或心血管事件风险升高。
- 感染后所有年龄层在1-2个月内出现心血管事件风险升高,老年人感染后>180天风险仍升高(aHR=1.18,95%CI=1.04-1.34)。
- 感染前180天内接种疫苗可减弱感染后急性期心血管风险,>180天时aHR=1.10(95%CI=0.95-1.07),未达统计学显著。
核心结论
- 奥密克戎时代任何mRNA疫苗接种后180天内未观察到全因死亡或心血管事件风险升高。
- 疫苗接种减弱了老年人感染后急性期心血管风险,奥密克戎期间疫苗接种的风险-获益比仍为正向。
研究设计与样本
- 回顾性队列研究,纳入2022年1月6日至12月31日奥密克戎主要传播期间≥18岁新加坡成年人。
- 共3,137,210名成年人参与,接种2,047,008剂疫苗(99%为加强针),记录1,189,846例感染。
- 采用Cox回归模型校正人口学特征和合并症,估计mRNA疫苗接种或SARS-CoV-2感染后0-180天全因死亡和心血管事件风险,对照为mRNA疫苗接种后>180天。
主要发现
- 共记录23,028例死亡和54,017例心脏事件。
- 疫苗接种后各年龄层均未观察到全因死亡或心血管事件风险升高。
- 感染后老年人(≥60岁)全因死亡风险升高持续至>180天,对照为疫苗接种后>180天的人时。
- 对于接种后<180天发生疫苗突破性感染的老年人,死亡风险仅在感染后60天内升高,之后不再升高。
- 任何SARS-CoV-2感染后1-2个月所有年龄层心血管事件风险升高,老年人感染后>180天风险仍升高(aHR=1.18,95%CI=1.04-1.34);感染前180天内接种疫苗可减弱此风险,>180天时aHR=1.10(95%CI=0.95-1.07),未达统计学显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Assessing population-wide risk-benefit ratio of COVID-19 vaccination remains relevant in the current era of Omicron endemicity and boosting. Assessments of mortality risk and cardiovascular events post-vaccination/infection were generally made prior to emergence of milder Omicron and booster rollout. METHODS: Retrospective cohort study from 6th January to 31st December 2022 (Omicron-predominant transmission), amongst adult Singaporeans aged ≥18 years. Cox regression models adjusted for demographics/comorbidities were used to estimate risk of all-cause mortality and cardiovascular events 0-180 days post-mRNA vaccination/SARS-CoV-2 infection, compared to >180 days post-mRNA vaccination. Risk periods post-vaccination were further stratified by presence/absence of SARS-CoV-2 infection in the preceding 180 days; similarly, risk periods post-infection were further stratified by vaccination in the 180 days preceding infection. RESULTS: 3,137,210 adults participated, with 2,047,008 vaccine doses administered (99 % being booster doses) and 1,189,846 infections. 23,028 deaths and 54,017 cardiac events were recorded. No elevated risk of all-cause mortality/cardiovascular events was observed across all age strata post-vaccination. Conversely, all-cause mortality post-infection remained elevated up to >180 days in older adults (≥60 years), compared to person-time > 180 days post-vaccination. For vaccine-breakthrough SARS-CoV-2 infection in older adults vaccinated <180 days prior, risk of mortality was only elevated up to 60 days post-infection, but not beyond. Elevated risk of cardiovascular events 1-2 months after any SARS-CoV-2 infection was observed across all age strata, with elevated risk observed in older adults >180 days post-infection (adjusted-hazards-ratio, aHR = 1.18, 95 %CI = 1.04-1.34). Preceding vaccination within 180 days prior to infection attenuated this risk, with no significantly elevated post-acute risk of cardiovascular events (>180 days: aHR = 1.10, 95 %CI = 0.95-1.07). CONCLUSION: No increased risk of all-cause mortality or cardiovascular events was observed up to 180 days after any mRNA vaccination dose in the Omicron era; vaccination attenuated post-acute cardiovascular risk in older adults. The risk-benefit ratio of vaccination remained positive during Omicron.
引用
- Wee LE, Malek MIBA, Tan J, et al. Risk of death and cardiovascular events following COVID-19 vaccination or positive SARS-CoV-2 test amongst adult Singaporeans during omicron transmission. Vaccine. 2024. PMID: 39299002. doi:10.1016/j.vaccine.2024.126356
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。